Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production
- 1 March 2001
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 280 (3) , E540-E547
- https://doi.org/10.1152/ajpendo.2001.280.3.e540
Abstract
Our objective was to examine very low density lipoprotein-triglyceride (VLDL-TG) kinetics after chronic and acute administration of nicotinic acid (NA). Incorporation of [1,2,3,4-13C4]palmitate and [2-13C1]glycerol into VLDL-TG was measured in five healthy, normolipidemic women. Each subject was studied twice; the 4-day hospital stays were separated by 1 mo, during which time doses of NA were increased to 2 g/day (500 mg, 4 times/day). During posttreatment study, 500 mg of NA were administered acutely at 0800. Under baseline postabsorptive conditions, incorporation curves from13C-labeled free fatty acid (FFA) and13C-labeled glycerol were superimposable, and VLDL-TG kinetics were in agreement ( t1/2= 1.4 ± 0.3 and 1.3 ± 0.3 h, and production rates = 27.2 ± 6.1 and 28.5 ± 5.3 g/day, respectively). In the postabsorptive state after chronic NA therapy, VLDL-TG concentrations and production rates were lower despite a trend toward elevated plasma FFA concentrations and fluxes. After the acute dose of NA, plasma FFA concentrations and flux fell dramatically, and there was a virtual halt to VLDL-TG production, which continued throughout the 6-h period after NA, despite a marked rebound overshoot in serum FFA concentrations and flux after hour 2. Plasma homocysteine concentrations increased 68% ( P < 0.001) in the NA phase, consistent with chronic increased transmethylation demand. We conclude that 1) NA acutely and chronically decreases VLDL-TG production rate in normal women; 2) the acute effect on VLDL-TG production is associated with an initial suppression of lipolysis but persists for several hours after the antilipolytic action of NA has abated and is observed in the basal postabsorptive state, when lipolytic rates are not reduced; and 3) the effect of NA on VLDL-TG production, therefore, cannot be completely explained by its antilipolytic actions.Keywords
This publication has 34 references indexed in Scilit:
- Do Lipid Lowering Drugs Reduce the Risk of Coronary Heart Disease?Critical Reviews in Clinical Laboratory Sciences, 1998
- Short-term alterations in carbohydrate energy intake in humans. Striking effects on hepatic glucose production, de novo lipogenesis, lipolysis, and whole-body fuel selection.Journal of Clinical Investigation, 1995
- Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans.Journal of Clinical Investigation, 1995
- One-year reduction and longitudinal analysis of carotid intima-media thickness associated with colestipol/niacin therapy.Stroke, 1993
- Different Acute and Chronic Effects of Acipimox Treatment on Glucose and Lipid Metabolism in Patients with Type 2 DiabetesDiabetic Medicine, 1993
- Use of Niacin as a DrugAnnual Review of Nutrition, 1991
- Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacinJournal of the American College of Cardiology, 1986
- Kinetic model for production and metabolism of very low density lipoprotein triglycerides. Evidence for a slow production pathway and results for normolipidemic subjects.Journal of Clinical Investigation, 1979
- Acute Effects of Nicotinic Acid in the RatActa Medica Scandinavica, 1966
- The Effect of Nicotinic Acid on the Plasma Free Fatty Acids Demonstration of a Metabolic Type of SympathicolysisActa Medica Scandinavica, 1962